Anna Tomczyk represents issuers and underwriters on public and private securities offerings, including initial public offerings, follow-on offerings and secondary public offerings, as well as Rule 144A and Regulation S offerings. Ms. Tomczyk also advises companies on mergers and acquisitions, corporate governance, periodic reporting and securities regulation and compliance. She counsels clients from a wide variety of industries, including life sciences, financial services and retail. 

    • BioAtla, Inc. (Nasdaq: “BCAB”) in its US$189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers).
    • VIA optronics AG, a leading supplier of enhanced display solutions, in its US$93.75 million cross-border initial public offering and listing on the NYSE.
    • Acacia Research Corporation (Nasdaq: "ACTG") in connection with its strategic partnership with Starboard Value, consisting of a financing providing Acacia with access to up to US$400 million of new capital for strategic investments and acquisitions.
    • B&G Foods in connection with its registered public offering of US$550 million in aggregate principal amount of 5.25% senior notes due 2027.
    • Zyla Life Sciences on securities law aspects in its merger with Assertio Therapeutics, Inc.
    • Sales Agents in multiple At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
    • OraSure Technologies, Inc. in its US$95 million public offering of common stock.
    • The underwriters in connection with Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD)’s US$25 million public offering of common stock.
    • Cowen and Company, as underwriter, in the US$97 million initial public offering of Boston Omaha Corporation. 
    • Minerva Neurosciences Inc. in its US$32 million initial public offering.
    • Piper Jaffray, as managing underwriter, in the US$40 million initial public offering of Tengion Inc.
    • Cowen and Company, as lead underwriter, in a US$55 million follow-on offering for TherapeuticsMD, Inc.
    • Cowen and Company, as lead underwriter, in US$15 million and US$30 million follow-on offerings for Trillium Therapeutics.
    • Cowen and Company, as sales agent, in at-the-market offerings for Amicus Therapeutics, Boston Omaha Corporation, Kempharm Inc., and Trillium Therapeutics Inc. 
    • Stifel, Nicolaus & Company, as lead underwriter, in a US$30 million follow-on offering for TherapeuticsMD, Inc.
    • RBC Capital Markets LLC, as lead underwriter, in a US$25 million follow-on offering for Kempharm Inc.
    • RBC Capital Markets LLC, as sales agent, in an at-the-market offering for Kempharm Inc.
    • The initial purchasers in a US$225 million offering of convertible senior notes for Amicus Therapeutics.
    • Anterios Inc. on its sale to Allergan.
    • A fishing supply company in its US$330 million high yield note offering.
    • Rexnord Corporation, in its US$500 million high yield note offering.
    • A mass customization conglomerate in its US$400 million senior note offering.
    • The underwriters, including Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley, UBS and Wells Fargo, in follow-on offerings of common stock and preferred stock of numerous international shipping and oil & gas companies, including Baltic Trading, Box Ships, Costamare, Dryships, Excel Maritime, GasLog, Ocean Rig, Safe Bulkers and Scorpio Bulkers. 
    • Jefferies, on securities law aspects of its US$10 billion merger of equals with Leucadia National Corporation. 

    Includes matters handled at Dechert or prior to joining the firm.